Bristol Myers Squibb participated in a series B round for the oncology drug developer that pushed its overall funding to $168m.
US-based cancer therapeutics developer Ikena Oncology secured $120m today in an oversubscribed series B round led by life sciences investment firm Omega Funds that included pharmaceutical firm Bristol Myers Squibb.
Financial services and investment group Fidelity Management & Research also took part, as did Surveyor Capital, Invus, Farallon Capital Management, BVF Partners, Cowen Healthcare Investments, Atlas Venture, OrbiMed, Logos Capital and HealthCor Management.
Ikena is developing biomarker-driven cancer drugs focused on a target in the KRAS signalling pathway, which is…
